Company expands therapeutic pipeline to 14 with new osteoporosis and atherosclerosis compounds.

BioLineRx signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis and BL-3050, a protein complex for the treatment of atherosclerosis.

This marks the third and fourth in-licensing agreements signed by BioLineRx since its IPO in February 2007, bringing the total number of drugs under development by the company to 14.

The worldwide, exclusive license agreements were signed with Yeda Research and Development, the technology transfer company of the Weizmann Institute of Science.

Previous articleEvoGenix Optimizes GSK Protein Product
Next articleBradley to Make a $7M Milestone Payment to BioSante and Antares